Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene

被引:29
作者
Olivier, S [1 ]
Fillet, M [1 ]
Malaise, M [1 ]
Piette, J [1 ]
Bours, V [1 ]
Merville, MP [1 ]
Franchimont, N [1 ]
机构
[1] Univ Liege, CHU Sart Tilman, CBIG, Lab Clin Chem & Human Genet,Dept Rheumatol, B-4000 Liege, Belgium
关键词
nitric oxide; ceramides; apoptosis; raloxifene; estrogen; osteoblast;
D O I
10.1016/j.bcp.2004.11.030
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Release of high levels of nitric oxide (NO) is associated with osteoblastic cell death. The mechanisms of NO-induced cytotoxicity are not well documented and it is presently not known if estrogenic compounds prevent this effect. We studied the role of ceramides in cell death induced by the NO donor sodium nitroprusside (SNP) and we tested the possibility that 17 beta-estradiol, the anti-estrogen ICI 182.780 and two selective estrogen receptor modulators raloxifene and tamoxifen modify osteoblastic cell apoptosis. SNP dose-dependently decreased MC3T3-E1 osteoblast viability, increased NO production in the culture media and enhanced the release of intracellular ceramides C22 and C24. Cell death induced by SNP was partially inhibited when MC3T3-E1 cells were pretreated. with raloxifene and tamoxifen but was not modified when the cells were pretreated with 17 beta-estradiol or ICI 182.780. Cell death induced by SNP resulted from apoptosis as demonstrated by Annexin-V and propidium iodide labeling and a reduction of SNP-induced MC3T3-E1 apoptosis was confirmed in the presence of raloxifene and tamoxifen. SNP induction of C22 and C24 production was inhibited by a pretreatment with raloxifene but not with 17 beta-estradiol. Moreover, the synthetic ceramide C24 (0.75 and 1 mu M) decreased MC3T3-E1 cell viability and osteoblast cell death induced by C24 was partially decreased by raloxifene and to a lesser extent by 17 beta-estradiol. These data demonstrate that SNP-induced cell death is mediated by the long chain ceramides C22 and C24 and that raloxifene protected osteoblast from apoptosis induced by SNP, an effect that might be relevant to its pharmacological properties on bone remodeling. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:891 / 901
页数:11
相关论文
共 51 条
[1]  
[Anonymous], N ENGL J MED
[2]   Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells [J].
Armour, KE ;
Ralston, SH .
ENDOCRINOLOGY, 1998, 139 (02) :799-802
[3]  
Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529-0131(200112)44:12<2790::AID-ART466>3.0.CO
[4]  
2-X
[5]  
BAFFET G, 1991, MOL BIOL MED, V8, P141
[6]   Role of the protein kinase C λ/ι isoform in nuclear factor-κB activation by interleukin-1β or tumor necrosis factor-α:: Cell type specificities [J].
Bonizzi, G ;
Piette, J ;
Schoonbroodt, S ;
Merville, MP ;
Bours, V .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (06) :713-720
[7]   Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells:: comparison of the effects of 17-β oestradiol and raloxifene [J].
Cheung, J ;
Mak, YT ;
Papaioannou, S ;
Evans, BAJ ;
Fogelman, I ;
Hampson, G .
JOURNAL OF ENDOCRINOLOGY, 2003, 177 (03) :423-433
[8]   REDUCTION OF THE MEMBRANE FLUIDITY OF HUMAN BREAST-CANCER CELLS BY TAMOXIFEN AND 17-BETA-ESTRADIOL [J].
CLARKE, R ;
VANDENBERG, HW ;
MURPHY, RF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (21) :1702-1705
[9]   Nitric oxide acts in conjunction with proinflammatory cytokines to promote cell death in osteoblasts [J].
Damoulis, PD ;
Hauschka, PV .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (03) :412-422
[10]   Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial [J].
Delmas, PD ;
Ensrud, KE ;
Adachi, JD ;
Harper, KD ;
Sarkar, S ;
Gennari, C ;
Reginster, JY ;
Pols, HAP ;
Recker, RR ;
Harris, ST ;
Wu, WT ;
Genant, HK ;
Black, DM ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3609-3617